# EDGAR Filing Document

**Accession Number:** 0001131399
**File Stem:** 0001654954-23-001199
**Filing Date:** 2023-2
**Character Count:** 12008
**Document Hash:** bb4a0422045d7d77a7005135b1e7f006
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001654954-23-001199.hdr.sgml**: 20230202

**ACCESSION NUMBER**: 0001654954-23-001199

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20230202

**FILED AS OF DATE**: 20230202

**DATE AS OF CHANGE**: 20230202

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** GSK PLC
- **CENTRAL INDEX KEY:** 0001131399
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** X0

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-15170
- **FILM NUMBER:** 23578730

**BUSINESS ADDRESS:**
- **STREET 1:** 980 GREAT WEST ROAD
- **CITY:** BRENTFORD MIDDLESEX
- **STATE:** X0
- **ZIP:** TW8 9GS
- **BUSINESS PHONE:** 011442080475000

**MAIL ADDRESS:**
- **STREET 1:** 980 GREAT WEST ROAD
- **CITY:** BRENTFORD MIDDLESEX
- **STATE:** X0
- **ZIP:** TW8 9GS

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** GLAXOSMITHKLINE PLC
- **DATE OF NAME CHANGE:** 20010105

**UNITED STATES**

 **SECURITIES AND EXCHANGE COMMISSION**

 **Washington, D.C. 20549**

 **Form 6-K**

 **REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16**

 **UNDER THE SECURITIES EXCHANGE ACT OF 1934**

For the month of February 2023

Commission File Number 001-15170

 **GSK plc**

(Translation of registrant's name into English)

 **980 Great West Road, Brentford, Middlesex, TW8 9GS**

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F . . . .X. . . . Form 40-F . . . . . . . .

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____

Issued: 2 February 2023, London UK

 ***Jesduvroq* (daprodustat) approved by US FDA for anaemia of chronic kidney disease in adults on dialysis**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

● *Jesduvroq* is the only oral HIF-PHI approved in the US, offering adults on dialysis with anaemia of chronic kidney disease a new oral treatment option

GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved *Jesduvroq* (daprodustat), an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), for the once-a-day treatment of anaemia due to chronic kidney disease (CKD) in adults who have been receiving dialysis for at least four months. *Jesduvroq* is the first innovative medicine for anaemia treatment in over 30 years and the only HIF-PHI approved in the US, providing a new oral, convenient option for patients in the US with anaemia of CKD on dialysis.

 **Tony Wood, President and Chief Scientific Officer, GSK, said:** "Over the last several decades, there has been little innovation in anaemia of CKD. We are proud to have developed *Jesduvroq* as a new oral treatment where there is a patient desire for more options."

The FDA approval is based on results from the ASCEND-D trial, assessing the efficacy and safety of *Jesduvroq* for the treatment of anaemia of CKD in patients on dialysis. <u>Results</u> were published in the *New England Journal of Medicine* with <u>additional results</u> published in the *New England Journal of Medicine* supplementary appendix.

CKD is an increasing global health burden affecting 700 million patients worldwide, with an estimated one in seven patients also developing anaemia.<sup>[1]</sup><sup>,</sup><sup>[2]</sup> When left untreated or undertreated, anaemia of CKD is associated with poor clinical outcomes and leads to a substantial burden on patients and healthcare systems.<sup>[3]</sup> There is an unmet need for oral treatment options with efficacy and safety comparable to current treatments.

 **LaVarne Burton, President and Chief Executive Officer, American Kidney Fund, said:** *"*Anaemia of CKD can be a debilitating condition that is challenging to manage. This news means that patients on dialysis who are living with anaemia of CKD now have another treatment option to help manage their anaemia."

A marketing authorisation application for daprodustat is currently under review with the European Medicines Agency, with a regulatory decision anticipated in the first half of 2023. In <u>June 2020</u>, daprodustat tablets were approved by Japan's Ministry of Health, Labour and Welfare for the treatment of patients with anaemia of CKD. In Japan, the brand name for daprodustat is *Duvroq*, where it is the market leader and preferred HIF-PHI.

 **About *Jesduvroq* (daprodustat)**

 *Jesduvroq*, a HIF-PHI, belongs to a novel class of oral medicines for the treatment of anaemia of CKD in adult patients on dialysis. Inhibition of oxygen-sensing prolyl hydroxylase enzymes stabilises hypoxia-inducible factors, which can lead to transcription of erythropoietin and other genes involved in the correction of anaemia, similar to the physiological effects that occur in the human body at high altitude.<sup>[4]</sup><sup>,</sup><sup>[5]</sup> *Jesduvroq* provides an oral treatment option for adult patients with anaemia of CKD on dialysis.<sup>[6]</sup> *Jesduvroq* is a tablet available in 5 dosage strengths: 1mg, 2mg, 4mg, 6mg, 8mg.

 **About the ASCEND Phase III clinical trial programme**

The ASCEND programme included five Phase III trials to assess the efficacy and safety profile of daprodustat for the treatment of anaemia of CKD across the disease spectrum. The programme enrolled over 8,000 patients who were treated for up to 4.26 years. Results from all five trials were presented at the American Society of Nephrology's Kidney Week 2021.

Results from the pivotal cardiovascular outcomes trial, ASCEND-D, which investigated patients on dialysis, were published in the *New England Journal of Medicine*:<sup>6</sup>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

● <u>ASCEND-D</u> (Anaemia Studies in CKD: Erythropoiesis via a Novel PHI Daprodustat-Dialysis) enrolled 2,964 dialysis patients with anaemia of CKD who were switched to receive daprodustat ESA control from a standard of care ESA therapy. A uniform iron management protocol was instituted across both arms of the study. The study met its primary efficacy and safety endpoints. Results showed daprodustatimproved or maintained Hb within target levels (10-11.5 g/dL) for these patients, and the primary safety analysis of the ITT population showed that daprodustatachieved non-inferiority of MACE compared to ESA control.

**About anaemia of chronic kidney disease**

<br> CKD is characterised by progressive loss of kidney function.<sup>[7]</sup> Anaemia is an important and frequent complication of CKD and is associated with increased morbidity, mortality and reduced quality of life.<sup>[8]</sup> It is often poorly diagnosed and undertreated in patients with early-stage CKD.<sup>[9]</sup> Over 700 million patients suffer from CKD worldwide, and an estimated 1-in-7 of these patients have anaemia.<sup>1,2</sup> CKD affects approximately 39 million people in the US, of whom approximately 6 million are also affected by anaemia.<sup>1,2</sup> There are approximately 810,000 patients who are end-stage renal disease (ESRD) in the US.<sup>[10]</sup> Of which, there are 558,000 patients receiving dialysis.<sup>10</sup> Of these patients receiving dialysis, 481,000 received hemodialysis and 77,000 received home or peritoneal dialysis.<sup>10</sup> When left untreated or undertreated, anaemia of CKD is associated with poor clinical outcomes and leads to a substantial burden on patients and healthcare systems.<sup>3</sup>

Please consult the full <u>Prescribing Information</u> including Boxed Warning and Medication Guide.

 **About GSK**

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at <u>gsk.com/company</u>

---

| | | | |
|:---|:---|:---|:---|
| **GSK enquiries** |  |  |  |
| Media: | Tim Foley | +44 (0) 20 8047 5502 | (London) |
|  | Dan Smith | +44 (0) 20 8047 5502 | (London) |
|  | Kathleen Quinn | +1 202 603 5003 | (Washington DC) |
|  | Lyndsay Meyer | +1 202 302 4595 | (Washington DC) |
| Investor Relations: | Nick Stone | +44 (0) 7717 618834 | (London) |
|  | James Dodwell | +44 (0) 20 8047 2406 | (London) |
|  | Mick Readey | +44 (0) 7990 339653 | (London) |
|  | Josh Williams | +44 (0) 7385 415719 | (London) |
|  | Jeff McLaughlin | +1 215 751 7002 | (Philadelphia) |
|  | Frannie DeFranco | +1 215 751 4855 | (Philadelphia) |

---

 **Cautionary statement regarding forward-looking statements**

GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described in the Company's Annual Report on Form 20-F for 2021, GSK's Q4 Results for 2022 and any impacts of the COVID-19 pandemic.

**Registered in England & Wales**

No. 3888792

 **Registered Office:**

980 Great West Road

Brentford, Middlesex

TW8 9GS

<sup>[1]</sup> Bikbov B, Purcell CA, Levey AS, et al. Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet*. 2020;395(10225):709-733.

<sup>[2]</sup> Stauffer et al. Prevalence of anemia in chronic kidney disease in the United States. *PLoS One.* 2014;9(1):e84943.

<sup>[3]</sup> Hanna RM et al. Burden of anemia in chronic kidney disease: beyond erythropoietin. *Adv Ther.* 2021;38(1):52-75.

<sup>[4]</sup> Ariazi JL, Duffy KJ, Adams DF, et al. Discovery and preclinical characterization of GSK1278863 (daprodustat), a small molecule hypoxia inducible factor-prolyl hydroxylase inhibitor for anemia. *J Pharmacol Exp Ther.* 2017;363(3):336-347.

<sup>[5]</sup> Maxwell PH, Eckardt KU. HIF prolyl hydroxylase inhibitors for the treatment of renal anaemia and beyond. *Nat Rev Nephrol.* 2016;12(3):157-168.

<sup>[6]</sup> Singh A, et al. Daprodustat for the Treatment of Anemia in Patients Undergoing Dialysis. *N Engl J Med.* 2021;385:2325-2335.

<sup>[7]</sup> Hill NR, Fatoba ST, Oke JL, et al. Global prevalence of chronic kidney disease - A systematic review and meta-analysis. *PLoS One*. 2016;11(7):e0158765.

<sup>[8]</sup> Palaka E, et al. The Impact of CKD Anaemia on Patients: Incidence, Risk Factors, and Clinical Outcomes-A Systematic Literature Review. *Int J Nephrol.* 2020 Jul 1;2020:769;2376

<sup>[9]</sup>St Peter WL, Guo H, Kabadi S, et al. Prevalence, treatment patterns, and healthcare resource utilization in Medicare and commercially insured non-dialysis-dependent chronic kidney disease patients with and without anemia in the United States. *BMC Nephrol*. 2018;19(1):67.

<sup>[10]</sup> United States Renal Data System. 2022 USRDS Annual Data Report: Epidemiology of kidney disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2022. Available at: https://usrds-adr.niddk.nih.gov/2022/end-stage-renal-disease/1-incidence-prevalence-patient-characteristics-and-treatment-modalities

 **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

---

| | |
|:---|:---|
|  | **GSK plc** |
|  | (Registrant) |
| Date: February 02, 2023 |  |
|  | By:/s/ VICTORIA WHYTE<br> -------------------------- |
|  | Victoria Whyte |
|  | Authorised Signatory for and on |
|  | behalf of GSK plc |

---